No Data
No Data
Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $80
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $80
BofA Adjusts Price Target on Ultragenyx Pharmaceutical to $80 From $83, Keeps Buy Rating
Ukrainian Minister Announces 'Significant Progress' in Minerals Deal Talks With US